UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K


              CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of report (Date of earliest event reported): October 23, 2014

                               CANNAPHARMARX, INC.
                              ---------------------
             (Exact name of Registrant as specified in its charter)

            Delaware                     000-27055                24-4635140
 ----------------------------    ------------------------   --------------------
 (State or other jurisdiction    (Commission File Number)   (IRS Employer Identi
       of incorporation)                                        -fication No.)

     One Collins Drive, Salem Business Center, Carneys Point, NJ 08069-3640
               --------------------------------------------------
                    (Address of principal executive offices)


                                  720-939-1133
        -----------------------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)

                            GOLDEN DRAGON HOLDING CO.
                        ---------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[_] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))









                 SECTION 5 - CORPORATE GOVERNANCE AND MANAGEMENT

Item 5.02  Departure of Directors or Certain  Officers;  Election of  Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officer

     On  October  23,  2014,  a  majority  of the  Board of  Directors  voted to
terminate  Gary Cohen as President of the Company.  Mr.  Cohen's  termination as
President was effective on October 23, 2014. Mr. Cohen remains a director of the
Company.

     On October 23, 2014, a majority of the Board of Directors  appointed Mathew
Sherwood a director of the Company. Mr. Sherwood's appointment as a director was
effective  October  23,  2014.  Mr.  Sherwood is our Vice  President  of Product
Development.

Mathew Sherwood, age 37

Vice President, Product Development and Director

     Mr.  Sherwood has more than 20 years of experience in  healthcare,  both in
private practice and as a consultant.  Mr. Sherwood worked as a  board-certified
optician  as well  as a  consultant  in both  practice  management  and  optical
laboratory  solutions.  As an optician,  Mr.  Sherwood  developed  solutions for
ophthalmic lens manufacturing and  high-performance  prescription  applications.
For most of the last  decade,  Mr.  Sherwood  has  turned  his focus to  medical
cannabinoid solutions,  developing a variety of cannabinoid-based solutions, and
has a deep understanding of the potential of cannabinoid products.  Mr. Sherwood
specializes in extraction technologies and the design and manufacturing of novel
delivery  systems.  Mr. Sherwood is a co-founder of the National  Association of
Cannabinoid Pharmaceuticals and continues to serve as an industry liaison.














                                     - 2 -






                                   SIGNATURES


         Pursuant to the  requirements  of the Securities  Exchange Act of 1934,
the  registrant  has duly  caused  this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                         CANNAPHARMRARX, INC.
                                         Formerly Golden Dragon Holding Co.


                                         By: /s/ Gerry Crocker
                                             -----------------------------------
                                             Chief Executive Officer



Date: October 24, 2014

























                                     - 3 -